Held by 6 specialist biotech funds
High Convergence**Signal Note: Driehaus Capital initiates BSX position** Driehaus's entry into Boston Scientific—a $372K position for a growth-focused fund with significant biotech exposure—suggests conviction in the company's near-term catalysts, likely tied to recent FDA approvals or clinical readouts in interventional cardiology/oncology (e.g., Ranger paclitaxel-coated balloon or Watchman device expansions).
AI analyst context — unlock full analysis
# Signal Note: OrbiMed Initiates $230.7M BSX Position OrbiMed's new 2.4M share stake in Boston Scientific suggests confidence in the company's interventional device pipeline, likely driven by recent positive clinical data or FDA decisions (e.g., recent approvals in structural heart or endoscopy segments). The $230.7M position size from a premier healthcare allocator may signal institutional conviction ahead of upcoming 2024-2025 catalysts, though without filed documentation details, the specific indication triggering this entry remains unclear.
+ 4more — see how much conviction went in
See the Full Story